Predicting the impact of microRNAs (miRNAs) on target proteins is challenging because of their different regulatory effects at the transcriptional and translational levels. In this study, we applied a novel protein lysate microarray (LMA) technology to systematically monitor for target protein levels after high-throughput transfections of 319 pre-miRs into breast cancer cells. We identified 21 miRNAs that downregulated the estrogen receptor-a (ERa), as validated by western blotting and quantitative real time-PCR, and by demonstrating the inhibition of estrogen-stimulated cell growth. Five potent ERa-regulating miRNAs, miR-18a, miR-18b, miR-193b, miR-206 and miR-302c, were confirmed to directly target ERa in 3 0 -untranslated region reporter assays. The gene expression signature that they repressed highly overlapped with that of a small interfering RNA against ERa, and across all the signatures tested, was most closely associated with the repression of known estrogen-induced genes. Furthermore, miR-18a and miR-18b showed higher levels of expression in ERa-negative as compared with ERapositive clinical tumors. In summary, we present systematic and direct functional evidence of miRNAs inhibiting ERa signaling in breast cancer, and demonstrate the highthroughput LMA technology as a novel, powerful technique in determining the relative impact of various miRNAs on key target proteins and associated cellular processes and pathways.
Introduction
MicroRNAs (miRNAs) are thought to be important regulators of protein expression. They target messenger RNAs (mRNAs) for either cleavage or translational repression by binding most often to the 3 0 -untranslated region (3 0 -UTR) (Esquela-Kerscher and Slack, 2006) . Genes encoding 706 human miRNAs have so far been identified (miRBase v.13.0) (Griffiths-Jones et al., 2008) , and they are predicted to regulate the expression of at least 60% of all human protein-encoding genes (Friedman et al., 2009) . A large number of bioinformatic methods have been developed to predict as to which miRNAs regulate which proteins (Bartel, 2009 ). However, these methods are highly unspecific and inaccurate, as miRNA sequences typically contain an imperfect match to the 3 0 -UTR of their target mRNA. The nature of miRNA regulation is complicated and networked, with a single miRNA predicted to target hundreds of proteins and a single protein influenced by multiple miRNAs (Baek et al., 2008; Selbach et al., 2008; Bartel, 2009) . Besides direct actions on the UTRs of target proteins, many miRNAs elicit secondary effects through other proteins. Finally, the biological context matters, not only the expression levels of target proteins but also that of a complex network associated with targets. Many efforts are underway to systematically characterize targets for miRNAs by using the transfection of anti-and pre-miRNAs into cells, followed by gene expression microarray analysis of target gene mRNAs (Lim et al., 2005; Linsley et al., 2007) . However, this method only captures the effects of miRNAs at the transcriptional level and is not affordable in the routine screening for effects of all miRNAs in specific cell lines or across multiple cell lines.
In this study, we introduce a protein lysate microarray (LMA)-based strategy for systems level estimation of the effects of more than 300 miRNAs on specific protein targets. In LMA, a library of pre-miRs is transiently transfected in 384-well plates into cells, and thereafter, the cells are lysed and protein lysates are printed on nitrocellulose-coated slides. The effects of miRNAs on a target protein are measured using a specific antibody staining of the array. We chose to study miRNAs impacting on estrogen receptor-a (ERa), which is an important factor determining the development, progression and treatment of breast cancer. ERa is the primary mediator of the mitogenic activities of estrogen in breast tissue, and its levels are tightly controlled in a tissue-and development-specific manner (Couse and Korach, 1999) . Multiple mechanisms are known to regulate ERa levels in cells, including transcriptional control (Reid et al., 2002) , rate of mRNA degradation (Kenealy et al., 2000) and, according to recent evidence, miRNAs (Adams et al., 2007; Liu et al., 2009) . Several miRNA expression studies have systematically analysed a large panel of miRNAs for their association with breast cancer progression and for their hormone receptor status (Mattie et al., 2006; Blenkiron et al., 2007; Verghese et al., 2008) . However, published functional studies have focused on the effects of a single miRNA at a time.
In this study, we confirmed the function of the previously characterized ERa-regulating miRNAs, miR18a and miR-206, which were validated using the LMA method. In addition, we identified 19 novel miRNAs as potent modulators of the ERa protein and mRNA levels in MCF-7 breast cancer cells. We also showed that miR18a, miR-18b, miR-193b, miR-206 and miR-302c directly targeted ERa by binding to its 3 0 -UTR region and used gene microarray analysis to show that these miRNAs inhibited the expression of ERa downstream genes. Finally, miR-18a and miR-18b expression levels were significantly higher in ERa-negative breast cancers in vivo, suggesting a role of these miRNAs in the development of ERa-negative breast cancers.
Results
LMA screens revealed several putative ERa-regulating miRNAs We applied LMA technology to systematically identify ERa-targeting miRNAs in two ERa-positive breast cancer cell lines. MCF-7 and BT-474 cells were transfected with a pre-miR miRNA library containing 319 pre-miR constructs mimicking endogenous miRNAs. The precursors in the library corresponded to all the human miRNAs in miRBase Sequence Database version 8.0. After 48 and 72 h of incubation, the cells were lysed and lysates were printed on nitrocellulosecoated slides and stained with a specific antibody against ERa. The slides were also counterstained with Sypro Ruby to normalize the levels of ERa for total protein ( Figure 1a and Supplementary Figure S1 ). With the LMA screening, we initially identified 60 miRNAs that reduced the expression of ERa at a 48 h time point, whereas 93 were observed at 72 h (Figure 1b) . The small interfering RNA (siRNA) for ERa (siERa) was used as a positive control for protein downregulation. Among the miRNAs that downregulated ERa at both time points were miR-206 and miR-18a, which have previously been shown to directly target ERa in breast cancer and hepatocellular carcinoma cells, respectively (Adams et al., 2007; Liu et al., 2009) (Figure 1b) . Furthermore, miRNAs predicted to target ERa were enriched among the ERa-downregulating miRNAs ( Figure 1c) . Two sample Wilcoxon test P-values for the enrichment were highly significant for MCF-7 cells at 48 and 72 h time points (Po2.1e-06 and Po1.2e-06, respectively). The P-values for BT-474 were also significant (not shown).
Validation of LMA data by assessment of the protein and mRNA level of ERa To validate the primary LMA data, we selected miRNAs that were identified in at least two replicate screens as putative ERa-downregulating miRNAs. As an additional selection criteria, target predictions from TargetScan (Grimson et al., 2007) , PicTar (Krek et al., 2005) and MiRanda (Betel et al., 2008) were used. This combined selection resulted in 21 miRNAs (Table 1) , which were further confirmed to downregulate ERa protein in MCF-7 and BT-474 cells by up to 80% by western blotting (Figure 2a ). Transfections of pre-miR constructs for miR-200a and miR-200b, which were not predicted to target ERa and did not score positive in the LMA screens, served as negative controls (Figure 2a) . We also confirmed the transfection efficiency of individual pre-miRs by Taqman miRNA assays, which detect only mature miRNAs. Transfection of precursors resulted in a significant overexpression of mature miRNAs, regardless of the levels of endogenous miRNAs (Supplementary Figure S2 and Supplementary  Table SIII) .
In addition to translational repression, miRNAs regulate gene expression by targeting mRNAs for cleavage. We therefore examined the effect of pre-miR overexpression on levels of ERa mRNA using quantitative real-time-PCR. Transfection of MCF-7 cells with siERa reduced ERa mRNA by twofold (Figure 2b ). All the 21 miRNAs downregulated the levels of ERa mRNA, suggesting that they target ERa mRNA to degradation. Negative control miRNAs, miR-200a/b, did not significantly affect ERa mRNA in MCF-7 cells (Figure 2b ). These validation experiments corroborated the power of LMA technology to search for miRNAs targeting a specific marker protein.
miRNA-mediated downregulation of ERa suppresses the estrogen-stimulated growth of MCF-7 cells Estrogen stimulates the proliferation of hormonedependent breast cancer cells, and this is mediated primarily by ERa (Couse and Korach, 1999) . To study the functional significance of ERa-downregulating miRNAs, we analysed whether the downregulation of ERa could inhibit the growth stimulatory effects of estrogen on MCF-7 cell growth. For that purpose, MCF-7 cells were first cultured in hormone-free growth media for 24 h, and then transfected with pre-miR constructs. After an additional 24 h incubation, the cells were treated with estrogen 17b-estradiol (2 nM) or with vehicle (dimethylsulfoxide) for 72 h. Estrogen stimulation enhanced the growth of negative control pre-miR-transfected MCF-7 cells by 2.4-fold, whereas pretreatment of cells with 4 0 OH-Tamoxifen totally suppressed the estrogen-stimulated growth. When ERa was knocked down with siERa, the estrogen-induced growth was inhibited by 60% (Figure 3 ). Most miRNAs showed a similar or slightly lower inhibition than did siERa. Transfection of cells with a siRNA for ERb had no significant effect, confirming that growth inhibition was dependent on ERa.
miR-18a, miR-18b, miR-193b and miR-206 induce the accumulation of MCF-7 cells in the G 1 /G 0 phase of the cell cycle In the absence of estrogens or in the presence of antiestrogens, proliferation of hormone-dependent breast cancer cells is inhibited and they accumulate in the G 1 phase of the cell cycle (Doisneau-Sixou et al., 2003) . Therefore, we studied how a downregulation of ERa by miRNAs affects the cell cycle of MCF-7 cells. Cells were transfected with pre-miR constructs for all the 21 ERa-downregulating miRNAs, and cell cycle distribution was analysed after 48 h by fluorescenceactivated cell sorting. The strongest inhibitors were miR-18a, miR-18b, miR-193b and miR-206, which significantly increased the fraction of cells in the G 1 / G 0 phase (68-80%), as compared with 47% G 1 /G 0 fraction in controls (Figure 4 and Supplementary Table  SIV) . These data were comparable with the results for siRNA-mediated ERa knockdown as well as with 4 0 OHTamoxifen-treated samples ( Figure 4 and Supplementary Table SIV) . Interestingly, the majority of ERadownregulating miRNAs had no effect on the cell cycle distribution of MCF-7 cells, suggesting that they might target other genes that balance their antimitogenic effect on ERa.
miR-18a, miR-193b, miR-206 and miR-302c repress ERa-responsive genes Typically, miRNAs regulate the expression of hundreds of different genes, and often target several genes on the same pathways (Lewis et al., 2005) . To better understand the function of miRNAs in estrogen-mediated (a) MCF-7 and BT-474 breast cancer cells were transfected with premiR constructs (20 nM) and incubated for 48 h. Thereafter, the cells were lysed and lysates were analysed with western blotting for the expression of ERa. The relative levels of ERa protein quantitated with Odyssey software and normalized for b-actin are shown below the corresponding panels (scrambled control was arbitrarily set as 1.0). (b) MCF-7 breast cancer cells were transfected with pre-miR constructs and incubated for 24 h. Thereafter, total cellular RNAs were isolated and analysed with Taqman quantitative real-time-PCR for the expression of ERa mRNA. The results normalized for GAPDH are shown as relative expression using scrambled negative control miRNA (Scr) as a reference. Data were collected from two separate biological experiments, which were both run twice with triplicates (mean ± s.e.m.).
signal transduction, we examined their effects on the gene expression profile of MCF-7 cells using microarray. For the experiment, we selected miR-18a, miR-193b and miR-206 because of their cell cycle effect. In addition, miR-302c was included in the experiment because of its potent effect on ERa protein and mRNA, as well as on estrogen-induced growth. Cells were transfected with premiR constructs and siERa control and were incubated for 24 h, followed by analysis using Illumina gene expression BeadChips (Illumina Inc, San Diego, CA, USA).
A clustering analysis of all the differentially expressed genes revealed genes specifically downregulated by each miRNA (Supplementary Figure S3) . Furthermore, a consensus set of genes downregulated by all four miRNAs (miR-18a, miR-193b, miR-206 and miR302c) and siERa included many well-known ERaresponsive genes, such as MYB, GREB1, CD44, PDZK1, IGFBP4 and STC2. When the expression profiles were compared in an unbiased manner against profiles from the MSigDB database (Subramanian et al., 2005) using the Gene Set Analysis (GSA) software (Efron and Tibshirani, 2007) , the most systematically enriched signature among the miRNA-downregulated genes was an MSigDB signature, 'FRASOR_UP' (Figure 5 and Supplementary Table SV) . This signature originates from the treatment of MCF-7 cells with estrogen (Frasor et al., 2004) , and it contains ERadependent genes. This analysis indicates in an unbiased manner that ERa is an important target for the miRNAs identified in this study.
ERa is a direct target for miR-18a, miR-18b, miR-193b, miR-206 and miR-302c On the basis of TargetScan predictions (Grimson et al., 2007) , miR-18a and miR-18b have the highest scoring target sites in the 3 0 -UTR region of ERa. A conserved 8-mer site can be found at position 1938-1945 of the ERa 3 0 -UTR, with a context score percentile of 94%. In addition, the ERa 3 0 -UTR contains one nonconserved 8-mer site and one 7mer-1A site for miR-18a/b at positions 1917-1924 and 527-533, respectively. miR302c has a favorable target site in ERa 3 0 -UTR, with a context score percentile of 86%. miR-193b is predicted to target ERa by another algorithm, PicTar (Krek et al., 2005) , and it has a conserved, predicted 7-mer site at position 3999-4005 of the ERa 3 0 -UTR. As our studies suggested that miR-18a/b, miR-193b, miR-206 and miR-302c are highly effective modulators of ERa signaling, we analysed whether these five miRNAs directly target ERa. We cloned four separate fragments covering the ERa 3 0 -UTR region into a luciferase reporter vector (Figure 6a ). In addition, we designed B60mer oligos bearing the target sites for miR-18a/b, miR-193b, miR-206 and miR-302c, and cloned these into the luciferase reporter vector (Supplementary Table SII ). The resulting ERa 3 0 -UTR-luciferase constructs were transfected in MCF-7 cells, together with pre-miRs, and with a Renilla luciferase control plasmid. Transfection of miR-18a, miR-18b, miR-193b, miR-206 and miR-302c significantly inhibited the reporter activity of the constructs containing predicted sites for those miRNAs, as compared with scrambled miRNA-transfected negative control (Figure 6b ). Constructs not containing predicted sites were unaffected by transfection with a given miRNA, for example, contructs nos. 3 and 4 were unaffected by transfection with miR-18a or miR-18b (Figure 6b ). Similar results were obtained with shorter constructs containing B60-mer oligos spanning miRNA-binding sites in ERa 3 0 -UTR (Supplementary Figure S4) . These results confirm that miR-18a/b, miR-193b, miR-206 and miR-302c directly target ERa by binding to its 3 0 -UTR region. -18a, miR-193b, miR-206, miR-302c and siERa downregulate estrogen receptor-a (ERa)-responsive genes. MCF-7 cells were transfected with pre-miR constructs and siERa, and were incubated for 24 h. Thereafter, total cellular RNAs were subjected to gene expression analysis using Illumina BeadChips. The resulting global gene expression profiles were compared against profiles from the Molecular Signatures Database (MSigDB) using Gene Set Analysis (GSA) software. Across all the signatures tested, the most frequently enriched signature among miRNA-downregulated genes was an MSigDB signature 'FRASOR_UP', which originates from estrogen-treated MCF-7 cells, and which contains ERa-responsive genes. Shown are the expression values of genes from the 'FRASOR_UP' signature. The scale of downregulation (green signal) is represented in the color bar in the upper left hand corner of the figure.
miR-18a and miR-18b have a lower expression in ERa-positive tumors To determine the possible physiological role of ERaregulating miRNAs, we studied their expression in ERa-positive and ERa-negative breast cancers. For that purpose, we analysed the miRNA microarray expression data for miR-18a, miR-18b, miR-193b, miR-206 and miR-302c in 96 primary breast cancer specimens. The analysis was carried out both by dichotomizing tumors into ERa positive and ERa 0 -UTR. Reporters (100 ng) were co-transfected with pre-miR constructs (50 nM) for the indicated miRNAs, and luciferase activity was measured after 24 h incubation. Firefly luciferase activity was normalized to that of Renilla luciferase. The data shown are the mean±s.e.m. of three independent experiments, each performed in triplicate (*Po0.05, **Po0.01).
negative, and by correlating miRNA expression levels with the semiquantitative assessment of ERa immunostaining. With miR-193b, there was no association with ERa grading, and the expression of miR-302c and miR-206 could not be detected in the majority of primary tumors (data not shown). However, the results provided a statistically significant inverse association between the expression of miR-18a and miR-18b and that of ERa immunostaining (P ¼ 0.0001, 0.0004, respectively) ( Figure 7 ). This suggests that the expression of miR-18a and miR-18b might be an important in vivo regulatory mechanism of ERa in breast cancer patients.
Discussion
In this study, we describe high-throughput miRNA gain-of-function screening, followed by protein LMAs, to identify and validate miRNAs that target ERa in breast cancer cell lines. With LMA technology, we confirmed the function of previously characterized miRNAs regulating ERa expression (Adams et al., 2007; Zhao et al., 2008; Liu et al., 2009) , and also identified several novel miRNAs with similar effects. Although these previous studies have already pointed to individual miRNAs that may regulate ERa protein, this is the first study in which the effects of an entire library of pre-miRs were systematically tested and their effects were compared with one another and across two time points and in two cell lines. Our functional studies therefore significantly expand the previous studies exploring the impact of individual miRNAs impacting ERa expression.
These analyses demonstrate how this technology provides a powerful approach for a systematic analysis of a library of miRNAs for their cellular effects on specific targets or pathways in a single experiment. Various computational algorithms to predict miRNA targets have been developed, such as TargetScan (Grimson et al., 2007) , PicTar (Krek et al., 2005) and MiRanda (Betel et al., 2008) . The bioinformatic prediction of miRNA targets remains challenging, as miRNA sequences typically contain an imperfect match to the 3 0 -UTR of their target mRNAs. Therefore, highthroughput laboratory methods for an experimental validation of miRNA targets are required to facilitate miRNA research and to understand the complex systems biology of this type of gene regulation. Microarray-based gene expression analyses will miss target genes that are regulated solely at the translational level. Recently, proteomic profiling of human cells with SILAC after miRNA transfections revealed how individual miRNAs modulated the levels of hundreds of proteins (Baek et al., 2008; Selbach et al., 2008) . However, proteomic analyses are biased toward more abundant proteins, and quantitative comparisons between multiple miRNA experiments remain challenging. Therefore, LMA-based analysis provides a quantitative method for the rapid identification of miRNAs regulating specific target proteins and a comparison of the degree of effects of individual miRNAs across different proteins and across different cell types. In multicolor immunostaining, several targets could be profiled at a time, with consecutive LMA slides allowing the profiling of dozens of targets as well as of phenotypic indicators, such as proliferation, apoptosis and cell differentiation.
In this study, we initially identified a large number of hits targeting ERa, when MCF-7 and BT-474 cells were screened with 319 human pre-miRNAs, and cell lysates were analysed for downregulating the ERa protein. The large number of miRNA hits is likely due to the fact that miRNAs generally target several genes and pathways, Figure 7 The expression of miR-18a and miR-18b shows inverse correlation with estrogen receptor-a (ERa). Ninety-six (96) primary breast cancer specimens were analysed for microRNA (miRNA) expression using Agilent miRNA microarray. The analysis was carried out both by dichotomizing the tumors into ERa positive and ERa negative, as well as by correlating miRNA expression levels with the semiquantitative assessment of ERa immunostaining. The tumors were graded (0-4) by immunohistochemical (IHC) staining of ERa, depending on the percentage of cell nuclei that were stained (0, 0%; 1, 1-10%; 2, 10-50%; 3, 50-75%; 4, 75-100%). Boxplots show the expression of hsa-miR-18a (left panel) and hsa-miR-18b (right panel) in relation to ERa grading. Open dots indicate outliers.
and hence, many of the miRNAs may target other genes, which then indirectly downregulate the ERa expression. There was, however, a significant enrichment of predicted miRNAs among the hits. Only these hits were further explored, as they were most likely to be primary regulators of ERa. Besides the direct effects on ERa protein, we showed how miR-18a, miR-18b, miR193b and miR-206 specifically induced cell cycle arrest and inhibited estrogen-induced proliferation, with inhibition levels comparable with that of siERa. The gene expression analyses demonstrated that miR-18a, miR193b, miR-206 and miR-302c downregulated a common set of estrogen-responsive genes and had similar transcriptional effects as that of siERa. We also showed that miR-18a, miR-18b, miR-206, miR-193b and miR302c directly target ERa by associating with the ERa 3 0 -UTR region. Our results suggest that these miRNAs have a crucial and direct role in modulating the ERa protein in breast cancer cells and that they lead to a silencing of ERa signaling and inhibition of estrogendependent cell growth. Furthermore, in a cohort of 96 clinical breast tumor samples, there was a significant association between the high expression of miR-18a and miR-18b and ERa-negative breast cancers, suggesting that some of the miRNAs identified here may participate in the silencing of ERa during breast cancer progression in vivo.
Our functional studies significantly expand the previous studies exploring the miRNA expression in breast cancer and the association of miRNAs with ER status and estrogen-regulated cell growth. miRNA expression has been shown to distinguish different breast cancer subtypes, including the typically ERa-positive luminal A and B subtypes, and several miRNAs have been associated as being differently expressed between ERapositive and -negative breast tumors (Blenkiron et al., 2007) . Kondo et al. (2008) have reported that miR-206 has a lower expression in ERa-positive than in ERanegative breast cancers (Kondo et al., 2008) . In our study, miR-206 expression was detected in less than 27% of tumors, and no significant anti-correlation with the ERa status was observed.
Understanding the molecular basis of ER expression is critically important, as most breast cancers express high levels of ERa, and the inhibition of estrogenic signals by antiestrogens and other endocrine therapies is an important part of the management of breast cancer patients. However, many patients relapse during endocrine therapies and develop estrogen-independent breast cancer (Milano et al., 2006) . Therefore, a better mechanistic understanding of ERa regulation, as well as novel ways to inhibit estrogen-dependent breast cancer growth, is important. In summary, our studies using LMA screening technology have identified miRNAs that are potent negative regulators of ERa expression and that serve as efficient inhibitors of the ERa function. As inhibition of the ERa function is a key therapeutic option, these results may provide new insights, mechanisms and biomolecules to enhance the inhibition of estrogen-dependent breast cancer growth, tumor development and progression.
Materials and methods
Cell culture and reagents MCF-7 cells were obtained from Interlab Cell Line Collection (ICLC, Genova, Italy) and BT-474 from American Type Culture Collection (ATCC, Manassas, VA, USA). MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (1 g/l glucose) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin. BT-474 cells were cultured in Dulbecco's modified Eagle's medium (4.5 g/l glucose) supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 0.01 mg/ml insulin, 1 mM Na-pyruvate and 1% penicillin/streptomycin.
Human Pre-miR miRNA precursors and siRNA for human ERa (GGCCAAAUUCAGAUAAUCGTT) were purchased from Ambion Inc. (Austin, TX, USA). b-estradiol and 4 0 OHTamoxifen were purchased from Sigma-Aldrich (St Louis, MO, USA).
LMA screening and data analysis A detailed description of LMA screening is provided in the Supplementary Information. Briefly, MCF-7 and BT-474 cells were transfected with 20 nM human Pre-miR miRNA Precursor library v2 (Ambion Inc.) containing 319 chemically modified double-stranded RNA molecules mimicking endogenous mature human miRNAs. After 48 or 72 h of incubation, cells were lysed and printed on nitrocellulosecoated microarray FAST slides (Whatman Inc., Florham Park, NJ, USA). The ERa protein expression was detected by staining the slides with an ERa antibody (Ab-15; Labvision Corp, Fremont, CA, USA), followed by exposure to Alexa Fluor 680-tagged secondary antibody (Invitrogen Inc., Carlsbad, CA, USA). For total protein measurement, arrays were stained with Sypro Ruby Blot solution (Invitrogen). The slides were scanned with a Tecan LS400 (Tecan Inc., Durham, NC, USA) microarray scanner and an Odyssey Licor IR-scanner (LI-COR Biosciences, Lincoln, NE, USA) to detect Sypro and ERa signals, respectively. Array-Pro Analyzer microarray analysis software (Median Cybernetics Inc., Bethesda, MD, USA) was used for analysing data.
TargetScan v.4.2 (Grimson et al., 2007) and mirDB v.2.0 (Wang and El Naqa, 2008) were used for miRNA target predictions. Enrichment factor and P-value according to hypergeometric distribution were calculated using the minimum Z-score value of negative control miRNAs as a threshold. The two sample Wilcoxon test was used to show that the miRNAs predicted to target ERa were more effective in reducing ERa levels than the miRNAs not predicted to target ERa.
Immunoblotting Aliquots of total cell lysates were fractionated on SDSpolyacrylamide gels and were transferred to Whatman Protran nitrocellulose membranes (Schleicher & Schuell, Whatman Inc, Florham Park, NJ, USA) . Filters were blocked against nonspecific binding using 5% skimmed milk. Membranes were probed with a specific antibody for human ERa (Labvision Corp). Equal loading was confirmed by probing the same filter with a specific antibody for human b-actin (Sigma-Aldrich). Signals were obtained by incubating the filters with secondary antibody Alexa Fluor 680 anti-mouse IgG (Invitrogen) and scanning the filters with Odyssey Licor. The relative levels of ERa protein were quantitated with Odyssey LI-COR 2.1 software and normalized for b-actin.
Quantitative Real-time-PCR analysis Total cellular RNAs were isolated with a MiRVana Total RNA isolation kit (Ambion Inc.). For cDNA synthesis, 200 ng of total RNA was reverse transcribed with a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Thereafter, the cDNAs were diluted 1/10 and Taqman quantitative real-time-PCR analysis was carried out with an Applied Biosystems 7900HT instrument using specific primers for ERa (ESR1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) designed by the Universal Probe Library Assay Design Center (Roche Applied Biosciences, Basel, Switzerland). The sequences of the primers were as follows: ESR1 forward 5 0 -TTACTGACCAACCTGGCAGA-3 0 , ESR1 reverse 5 0 -ATCATGGAGGGTCAAATCCA-3 0 , GAPDH forward 5 0 -AGCCACATCGCTCAGACA-3 0 , and GAPDH reverse 5 0 -GCCCAATACGACCAAATCC-3 0 . The fluorescent Taqman probes were obtained from Roche Human Probe Library (no. 24 for ESR1 and no. 60 for GAPDH). The results were analysed with SDS 2.3 and RQ manager softwares (Applied Biosystems), and the expression of ESR1 mRNA was determined by the relative quantitation method using GAPDH as an endogenous control. Data were collected from two separate biological experiments, which were both run twice with triplicates.
ER 3
0 -UTR reporter constructs and luciferase assays Four separate fragments covering the ERa 3 0 -UTR region were amplified from the genomic DNA of MCF-7 cells using specific primers for ER 3 0 -UTR (Supplementary Table SI 
Proliferation assays
For assaying the effect of miRNAs on the estrogen-stimulated growth of MCF-7 cells, cells were cultured in phenol red-free Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% charcoal-stripped fetal bovine serum and 2 mM L-glutamine. The cells (10 000 per well) growing on white, clear-bottom 96-well plates were transfected with 20 nM premiR constructs or with siERa using SiLentFect (Bio-Rad Laboratories, Hercules, CA, USA). After 24 h incubation, the cells were treated with 2 nM 17b-estradiol or dimethylsulfoxide for 72 h. The total cell number was assayed using the CellTiterGlo Cell Viability assay (Promega Corp.).
Cell cycle analysis
Cell cycle analyses were carried out from the nuclei preparations of MCF-7 cells. Cells (30 000 per well on 24-well plates) were transfected with 20 nM pre-miR constructs or with siERa and incubated for 48 h. Thereafter, the cells were trypsinized, processed for cell cycle analysis with a BD CycleTest Plus DNA reagent kit (BD Biosciences, San Jose, CA, USA) and examined for cell cycle distribution using FACSArray (BD Biosciences). Data were analysed using Multicycle software (Phoenix FlowSystems, San Diego, CA, USA).
Illumina gene expression and data analyses MCF-7 cells (300 000 per well on six-well plates) were transfected with siERa or with pre-miR constructs for miR18a, miR-193b, miR-206, miR-302c or scrambled pre-miR at 20 nM. After 24 h incubation, total RNAs were isolated with the MiRVana Total RNA Isolation kit (Ambion Inc.). For Illumina gene expression profiling, 400 ng of total RNA was amplified and labeled using the Illumina Total Prep RNA Amplification kit (Ambion Inc.) and hybridized onto Illumina Sentrix Human-6 Expression BeadChips. The microarray data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE14847.
Preprocessing and normalization of data were carried out as described in the Supplementary Information. Gene expression after siRNA or miRNA transfections was compared with that in the negative control in a pairwise manner using the empirical Bayes statistics implemented by eBayes function (Smyth, 2004) . The Gene Set Analysis (GSA) R package (Efron and Tibshirani, 2007) was used for defining enriched gene sets in the data, which were obtained from the Molecular Signatures Database (MSigDB, Broad Institute of MIT and Harvard, Cambridge, MA, USA) (Subramanian et al., 2005) . miRNA expression and immunohistochemistry analyses of breast cancer samples RNA from 96 breast cancer samples was extracted as described earlier (Srlie et al., 2006) . Samples were hybridized in two replicates on Human miRNA Microarray (v2) from Agilent Technologies (Santa Clara, CA, USA) according to the manufacturer's protocol (G4170-90010 v1.5). The slides were scanned using the Agilent Microarray Scanner (G2565A) at 100 and 5% PMT. Feature Extraction v9.5.3.1 was used to extract signal intensities and to filter detectable miRNAs. Tumors were graded by immunohistochemical staining of ERa, depending on the percentage of ERa-positive nuclei (Naume et al., 2001) . Twenty-eight tumors were ERa negative, and 68 tumors with staining over 1% were considered as ERa positive. Of these, 8 tumors had 1-10%, 9 tumors had 10-50%, 11 tumors 50-75% and 40 tumors had 75-100% cells with ERa-positive staining. T-test and the nonparametric Kruskal-Wallis test were carried out for determining the association between miRNA expression level and ERa grading in SPSS 15.0 (SPSS Inc., Chicago, IL, USA).
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